Abstracts Archive - Page 479 of 2607 - ACR Meeting Abstracts

Abstract Number: 2602 • ACR Convergence 2023
Spatially Resolved Cellular Signatures Predict Corticosteroid Treatment Response in Giant Cell Arteritis
Cecilia Ansalone¹, Sam McAllister², Ethan Pickerill³, Lin Zhang³, Annie Peacock², Dominic McGovern⁴, Holly Leslie⁵, Victoria Kellior², Evelyn Qian², David Gemperline³, Aysin Tulunay Virlan², Sylvia Wright⁶, Paul Cauchi⁶, Timothy Beckman⁶, Lisa Hutton⁶, John Cole¹, Isabella Wulur³, Robert Benschop³, Nigel Jamieson⁵, Carl Goodyear¹ and Neil Basu¹, ¹University of Glasgow, Glasgow, United Kingdom, ²University of Glasgow - School of Infection & Immunity, Glasgow, United Kingdom, ³Eli Lilly and Company, Indianapolis, IN, ⁴University of Glasgow - School of Medicine, Glasgow, United Kingdom, ⁵University of Glasgow - School of Cancer Sciences, Glasgow, United Kingdom, ⁶NHS Greater Glasgow and Clyde, Glasgow, United Kingdom
Background/Purpose: Corticosteroids (CS) remain the mainstay of giant cell arteritis (GCA) therapy. Between ~30-70% patients relapse following CS taper and are consequently at risk of…
Abstract Number: PP11 • ACR Convergence 2023
We Suffered For Decades, But Then She Was Born
Ian Stedman¹ and Barbara Stedman², ¹Canadian Autoinflammatory Network, Vaughan, ON, Canada, ²Canadian Autoinflammatory Network, Turkey Point, ON, Canada
Background/Purpose: I was born in 1981; my mother in 1949; and my grandmother in 1926. Our story runs at least four generations deep, that we…
Abstract Number: 2601 • ACR Convergence 2023
Identification of Giant Cell Arteritis Using Plasma Proteome Profiles Integrated with Machine Learning
kevin cunningham¹, Jaeyun Sung², Benjamin Hur², VINOD GUPTA², Matthew Koster², Cornelia M. Weyand³, David Cuthbertson⁴, Nader Khalidi⁵, Curry Koening⁶, Carol Langford⁷, Carol McAlear⁸, Paul Monach⁹, Larry Moreland¹⁰, Christian Pagnoux¹¹, Rennie Rhee⁸, Philip Seo¹², Peter Merkel⁸ and Kenneth Warrington², ¹University of Minnesota, Minneapolis, MN, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic School of Medicine and Stanford University, Rochester, MN, ⁴University of South Florida, Tampa, FL, ⁵McMaster University, Hamilton, ON, Canada, ⁶University of Texas Dell Medical School, Austin, TX, ⁷Cleveland Clinic, Cleveland, OH, ⁸University of Pennsylvania, Philadelphia, PA, ⁹VA Boston Healthcare System, Boston, MA, ¹⁰University of Colorado, Denver, CO, ¹¹Mount Sinai Hospital, Toronto, ON, Canada, ¹²Johns Hopkins University, Baltimore, MD
Background/Purpose: The availability of diagnostic laboratory tests and specific biomarkers of disease activity for giant cell arteritis (GCA) remains an area of unmet need. The…
Abstract Number: PP06 • ACR Convergence 2023
Dana’s Data Dashboard: Applying a Familiar Framework for Efficient and Effective Health Management
Dana Guglielmo, Los Angeles, CA
Background/Purpose: As a researcher and data analyst, I enjoy the meticulous attention to detail that my work requires. I love the process of collecting, analyzing,…
Abstract Number: 2477 • ACR Convergence 2023
Anifrolumab Normalizes the Type I Interferon Signature in a Cohort of Patients with Type I Interferonopathies
Sara Alehashemi¹, Alexi Baumgardner², Bita Shakoory³, Adriana Almeida de Jesus², Sophia Park², Kat Uss², Maria P. Robles⁴, Karin Palmblad⁵, Annacarine Horne⁵, Peter Brodin⁵, Shoghik Akoghlanian⁶, Roshini Abraham⁷, Peter Mustillo⁷, Lilliana Barillas-Arias⁸, Andrea Heras⁹, Theresa Wampler Muskardin¹⁰, Monica G. Lawrence¹¹, Hannah C. Mannem¹¹, Brian E. Nolan¹², Scott Canna¹³, Adam Reinhardt¹⁴, Bryce Binstadt¹⁵ and Raphaela Goldbach-Mansky¹⁶, ¹NIH/NIAID/TADS, Clarksville, MD, ²NIAID, NIH, Bethesda, MD, ³NIH, NIAID, Translational Autoinflammatory Disease Study Unit, Bethesda, MD, ⁴Indiana University, Indianapolis, IN, ⁵Karolinska University Hospital, Stockholm, Sweden, ⁶Nationwide Children's Hospital, Columbus, OH, ⁷Nationwide Children's Hospital, Columbus, OH, ⁸Albany Medical Center, Albany, NY, ⁹Weill Cornell Medicine, New York, NY, ¹⁰Hospital for Special Surgery, New York, NY, ¹¹University of Virginia, Charlottesville, VA, ¹²Lurie Children’s Hospital, Chicago, IL, ¹³Children's Hospital of Philadelphia, Philadelphia, PA, ¹⁴Boys Town National Research Hospital, Omaha, NE, ¹⁵University of Minnesota, Minneapolis, MN, ¹⁶NIH/NIAID, Potomac, MD
Background/Purpose: Autoinflammatory Type I Interferonopathies (IFNopathies) include SAVI (STING-associated vasculopathy with onset in infancy), CANDLE/PRASS (Chronic atypical neutrophilic dermatosis, with lipodystrophy and elevated temperature), and…
Abstract Number: 2604 • ACR Convergence 2023
Premature Vascular Smooth Muscle Cells Senescence Driven by Interleukin-6-Mitochondrial STAT3-Mitofusin 2 Signaling in Takayasu’s Arteritis
Chenglong Fang¹, Lihong Du¹, Lili Li², Yuexin Chen³, Zuoguan Chen⁴, Yongjun Li⁴, Jing Li¹, Mengtao Li⁵, xiaofeng Zeng⁶ and Xinping Tian⁵, ¹Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China, ²The State Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and School of Basic Medicine, Peking Union Medical College, Beijing, China, ³Department of Vascular Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China, ⁴Department of Vascular Surgery, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China, ⁵Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ⁶Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Background/Purpose: Takayasu’s arteritis (TAK) is characterized by persistent vascular inflammation involving aorta and its main branches, which is an important prosenescent factor that in turn…
Abstract Number: 2247 • ACR Convergence 2023
Gender Differences in Switching Biological and Targeted Synthetic Therapies in Psoriatic Arthritis
Leticia Leon¹, Dalifer Freites², Maria Rodriguez Laguna³, Cristina Martinez⁴, Esther Toledano⁴, Inmaculada Morado³, Benjamin Fernandez³ and lydia Abasolo², ¹Fundación Investigación Biomédica Hospital Clínico San Carlos, Madrid, Spain, ²Hospital Clínico San Carlos, Madrid, Spain, ³Hospital Clinico San Carlos, Madrid, Spain, ⁴Hospital Clinico San Carlos, Rheumatology Deparment, Madrid, Spain
Background/Purpose: The impact of gender on biological and targeted synthetic therapies (ts/bDMARDs) used in PsA patients has been scarce studied. Our main objective was to…
Abstract Number: 2246 • ACR Convergence 2023
Real-World Switching and Discontinuation Patterns for Biologic Disease-Modifying Antirheumatic Drugs in Patients with Active Psoriatic Arthritis in Japan
Lars Erik¹, Ahmed Soliman², Dominic Nunag³, Ralph Lippe⁴, Matthew Davis³ and Mitsumasa Kishimoto⁵, ¹Bispebjerg-Frederiksberg Hospital, Vedbæk, Denmark, ²AbbVie, Inc., North Chicago, IL, ³Medicus Economics, LLC, Milton, MA, ⁴AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ⁵Kyorin University School of Medicine, Yokohoma, Japan
Background/Purpose: The national prevalence of PsA among patients (pts) with psoriasis (PsO) in Japan is estimated to be 14.3%. Risankizumab (RZB) was approved for the…
Abstract Number: PP10 • ACR Convergence 2023
Saved by Plants: How a Necessary Lifestyle Change Led to a Happier Life with Decreased Rheumatoid Arthritis Pain and Fatigue
Shelley Fritz, Global Healthy Living Foundation, Nyack, NY
Background/Purpose: After my RA diagnosis over eleven years ago, I was optimistic that the first biologic DMARD I took would slow the progression of my…
Abstract Number: 2487 • ACR Convergence 2023
Phase 2 Safety and Efficacy of Subcutaneous (s.c.) Dose Ianalumab (VAY736; Anti-BAFFR mAb) Administered Monthly over 28 Weeks in Patients with Systemic Lupus Erythematosus (SLE) of Moderate-to-Severe Activity
Nan Shen¹, Stanislav Ignatenko², Alexander Gordienko³, Josefina Cortés Hernández⁴, Nancy Agmon-Levin⁵, Pongthorn Narongroeknawin⁶, Katarzyna Romanowska -Prochnicka⁷, Hana Ciferska⁸, Masanari Kodera⁹, James Cheng-Chung Wei¹⁰, Piotr Leszczynski¹¹, Joung-Liang Lan¹², Eduardo Mysler¹³, Rafal Wojciechowski¹⁴, Tunde Tarr¹⁵, Elena Vishneva¹⁶, Yi-Hsing Chen¹⁷, Yuko Kaneko¹⁸, Stephanie Finzel¹⁹, Alberta Hoi²⁰, Ajchara Koolvisoot²¹, Shin-Seok Lee²², Lie Dai²³, Hiroshi Kaneko²⁴, Bernadette Rojkovich²⁵, Lingyun Sun²⁶, Eugeny Zotkin²⁷, Jean-Francois Viallard²⁸, Masao Katayama²⁹, Berta Paula Magallares-Lopez³⁰, Tirtha Sengupta³¹, Carol Sips³² and Stephen J Oliver³², ¹Shanghai Institute of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University (SJTUSM), Shanghai, China, ²Charité Research Organisation GmbH, Berlin, Germany, ³SM Kirov Military Medical Academy, St. Petersburg, Russia, ⁴Lupus Unit, Rheumatology Department, Vall d’Hebron Hospitals, Barcelona, Spain, ⁵Yabludowicz Center for Autoimmune Disease, Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel, ⁶Rheumatic Disease Unit, Department of Internal Medicine, Phramongkutklao Hospital and College of Medicine, Bangkok, Thailand, ⁷Department of Systemic Connective Tissue Diseases, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland, ⁸Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁹Department of Dermatology, Japan Community Healthcare Organization Chukyo Hospital, Nagoya, Japan, ¹⁰Chung Shan Medical University Hospital, Department of Rheumatology, Taichung, Taiwan, ¹¹Department of Internal Medicine, Poznan University of Medicine Sciences, Poznan, PL, Poznań, Poland, ¹²China Medical University Hospital, Taichung, Taiwan, ¹³Organizacion Medica de Investigacion, Buenos Aires, Argentina, ¹⁴Department of Rheumatology and Systemic Connective Tissue Diseases, University Hospital No. 2, Bydgoszcz, Poland, ¹⁵Division of Clinical Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary, ¹⁶LLC Family Clinic, Yekaterinburg, RU, Yekaterinburg, Russia, ¹⁷Taichung Veterans General Hospital, Taichung, Taiwan, ¹⁸Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ¹⁹Department of Rheumatology and Clinical Immunology, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany, ²⁰Monash University, Department of Medicine, Sub-faculty of Clinical and Molecular Medicine, Melbourne, Australia, ²¹Division of Rheumatology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, ²²Chonnam National University Medical School & Hospital, Gwangju, South Korea, ²³Department of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China, ²⁴Division of Rheumatic Disease, National Center for Global Health and Medicine, Tokyo, Japan, ²⁵Department of Rheumatology and Physiotherapy, Polyclinic of the Hospitaller Brothers of St. John of God, Semmelweis University, Budapest, Hungary, ²⁶Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, ²⁷VA Nasonova Research Institute of Rheumatology, Moscow, Russia, ²⁸CHU de Bordeaux, Hôpital Haut-Lévêque, Pessac, France, ²⁹National Hospital Organization, Nagoya Medical Center, Nagoya, JP, Nagoya, Japan, ³⁰Department of Rheumatology, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain, ³¹Novartis Pharma India, Hyderabad, Hyderabad, India, ³²Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Ianalumab is a novel defucosylated human IgG1 mAb targeting the receptor for B cell Activating Factor belonging to the TNF Family (BAFF-R) providing potent…
Abstract Number: 2227 • ACR Convergence 2023
The Impact of Smoking Status on One Year Secukinumab Retention Rate in 1,684 Patients with PsA: Real-World Results from the EuroSpA Collaboration
Zohra Faizy Ahmadzay¹, Stylianos Georgiadis², Marion Pons², Merete Hetland², Bente Glintborg³, Jette Heberg², Sara Nysom Christiansen², Simon Horskjær Rasmussen², Anne Gitte Loft⁴, Isabel Castrejon⁵, Lucia Otero-Valera⁶, Jakub Zavada⁷, Karel Pavelka⁸, Heikki Relas⁹, Laura Kuusalo¹⁰, Burkhard Moeller¹¹, Michael Nissen¹², Ziga Rotar¹³, Katja Perdan Pirkmajer¹⁴, Daniela Santos Oliveira¹⁵, Ana Rita Cruz-Machado¹⁶, Brigitte Michelsen¹⁷, Eirik Kristianslund¹⁸, Bjorn Gudbjornsson¹⁹, Gerdur Maria Grondal²⁰, Karin Laas²¹, Pasoon Hellamand²², Ismail Sari²³, Daniela Di Giuseppe²⁴, Mikkel Østergaard²⁵ and Lykke Ørnbjerg², ¹Rigshospitalet Glostrup, University of Copenhagen, Glostrup, Denmark, ²Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, ³Rigshospitalet Glostrup, University of Copenhagen, Virum, Denmark, ⁴Aarhus University, Horsens, Denmark, ⁵Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁶Spanish Society of Rheumatology, Madrid, Spain, ⁷Institute of Rheumatology; Charles University, Prague, Czech Republic, ⁸Institut of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Praha, Czech Republic, ⁹Helsinki University Hospital, Helsinki, Finland, ¹⁰Division of Internal Medicine, Centre for Rheumatology and Clinical Immunology, University of Turku and Turku University Hospital, Turku, Finland, ¹¹Inselspital - University Hospital Bern, Bern, Switzerland, ¹²Geneva University Hospitals, Geneva, Switzerland, ¹³University Medical Centre Ljubljana, Ljubljana, Slovenia, ¹⁴Department of Rheumatology, University Medical Centre LJubljana, Ljubljana, Slovenia, ¹⁵Department of Medicine, Faculty of Medicine, University of Porto, Rheumatology Department, Centro Hospitalar e Universitário de São João, Porto, Portugal, ¹⁶Rheumatology and Metabolic Bone Diseases Department, Hospital de Santa Maria, CHULN, Academic Medical Center and ERN-ReCONNET; Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa; Reuma.pt Sociedade Portuuesa de Reumatologia, Lisbon, Portugal, ¹⁷Rigshospitalet Glostrup; Diakonhjemmet Hospital; Sørlandet Hospital, Copenhagen, Denmark, ¹⁸Diakonhjemmet Hospital, Oslo, Norway, ¹⁹Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, ²⁰Department for Rheumatology, Landspitali University Hospital, Reykjavik, Iceland, ²¹Department of Rheumatology, East-Tallinn Central Hospital, Tallinn, Estonia, ²²Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands, ²³Division of Rheumatology, Department of Internal Medicine, Dokuz Eylul University School of Medicine, Izmir, Turkey, ²⁴Karolinska Institutet, Stockholm, Sweden, ²⁵Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark
Background/Purpose: Smoking has been associated with higher disease activity, poorer treatment response, and drug retention rate among psoriatic arthritis (PsA) patients treated with Tumor Necrosis…
Abstract Number: 1856 • ACR Convergence 2023
Improving Recombinant Zoster Vaccination Rates in Patients Receiving Immunosuppressive Therapy in the Rheumatology Clinic at the Orlando VA Healthcare System – a Quality Improvement Project
Kathlyn Camargo Macias¹, Ravi Shahu Khal¹, Ariail Schmitz², Kathleen McCabe¹, Taylor Kann¹, Marilyn Mosquera³ and Ashwini Komarla⁴, ¹University of Central Florida, Orlando, FL, ²University of Central Florida, St. Cloud, FL, ³University of Central Florida, Casselberry, FL, ⁴ORLANDO VAMC, Orlando, FL
Background/Purpose: Herpes zoster is a painful rash that involves one to three adjacent dermatomes, secondary to reactivation of latent varicella-zoster virus (VZV). About 95 %…
Abstract Number: 2243 • ACR Convergence 2023
Ultrasound Enthesitis Responsiveness versus Clinical Enthesitis Responsiveness: Week 52 Results of an Exploratory Analysis from a Phase 3b Study in Patients with Psoriatic Arthritis
Maria Antonietta D'Agostino¹, Corine Gaillez², Georg Schett³, Maarten Boers⁴, Philippe Carron⁵, Peter Mandl⁶, JAVIER ROSA⁷, Esperanza Naredo⁸, Catherine Bakewell⁹, Weibin Bao¹⁰ and Philip Conaghan¹¹, ¹Division of Rheumatology - Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy, ²Novartis Pharma AG, Croissy Sur Seine, France, ³Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ⁴Amsterdam UMC, Vrije Universiteit, Amersfoort, Netherlands, ⁵UZ Gent, Gent, Belgium, ⁶Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, ⁷Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁸Hospital Fundación, Madrid, Spain, ⁹Intermountain Healthcare, Salt Lake City, UT, ¹⁰Novartis Pharmaceuticals Corporation, Hanover, NJ, ¹¹University of Leeds, Leeds, United Kingdom
Background/Purpose: Enthesitis is a key clinical and imaging hallmark in psoriatic arthritis (PsA). ULTIMATE (NCT02662985) demonstrated responsiveness of ultrasound (US) detected synovitis and enthesitis in…
Abstract Number: 2248 • ACR Convergence 2023
Primary Non-response in Psoriatic Arthritis Treated with Biologics and Targeted Synthetic Therapies in Daily Clinical Practice
lydia Abasolo¹, Leticia Leon², Maria Rodriguez Laguna³, Esther Toledano⁴, Gloria Candelas³, Cristina Martinez⁴, Maria Paula Alvarez Hernandez³, Benjamin Fernandez³ and Dalifer Freites¹, ¹Hospital Clínico San Carlos, Madrid, Spain, ²Fundación Investigación Biomédica Hospital Clínico San Carlos, Madrid, Spain, ³Hospital Clinico San Carlos, Madrid, Spain, ⁴Hospital Clinico San Carlos, Rheumatology Deparment, Madrid, Spain
Background/Purpose: In Psoriatic arthritis (PsA), patients who fail to respond to biologics and targeted synthetic therapies (ts/bDMARDs), switching to another ts/bDMARD should be considered. Failure…
Abstract Number: 1862 • ACR Convergence 2023
Significant Overlap of Inflammatory and Degenerative Features on Spinal Imaging Among Patients with Degenerative Spinal Disease, Diffuse Idiopathic Skeletal Hyperostosis and Radiographic Axial Spondyloarthritis
Nelly Ziade¹, Nikolaos Kougkas², Melanie Udod³, Styliani Tsiami⁴ and Xenofon Baraliakos³, ¹Saint-Joseph University, Beirut, Lebanon, ²4th Internal Department, Ippokratio Hospital, Aristotle University of Thesaaloniki, Thessaloniki, Greece, ³Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁴Ruhr-Universität Bochum and Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: Degenerative changes of the spine (DC), diffuse idiopathic skeletal hyperostosis (DISH) and radiographic axial Spondyloarthritis (r-axSpA) may present with overlapping inflammatory and degenerative findings…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].